Cellular Therapies: Revolutionizing Cancer Therapy, Part 1: Adoptive Cell Therapy - An Introduction

In this first of a four-part series describing cellular therapies for hematologic cancers, Carl  H. June, MD, Richard W. Vague Professor in Immunotherapy at Penn Medicine, provides an introduction to current adoptive cell therapies in the hematologic malignancies with a concentration on CAR T cells, and discusses the characteristics of the optimal approach to CAR T therapy.

To view other parts of this program:

Part 2: CTL019 Therapy in Chronic Lymphocytic Leukemia

Part 3: CTL019 in Relapsed Refractory Pediatric Acute Lymphoblastic Leukemia

Part 4: Adoptive Cell Therapy - Lessons Learned, Issues and the Future

 

Related Links

• Clinical Briefing: Enrolling Clinical Trials: Adoptive Immunotherapy for Chemotherapy Resistant or Refractory CD-19+ Leukemia and Lymphoma
• Case Study: A 65-year-old male is treated with CD-19 chimeric antigen receptor T-cell therapy for purine-refractory CLL
• Dr. June's Profile